Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
Recent ANAB News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 08:10:15 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:22:41 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 12:09:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 09:50:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 09:48:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 08:20:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 08:17:24 PM
- Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/12/2026 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 08:05:24 PM
- Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors • GlobeNewswire Inc. • 05/11/2026 01:15:00 PM
- Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference • GlobeNewswire Inc. • 05/04/2026 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/29/2026 08:05:06 PM
- Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence • PR Newswire (US) • 04/28/2026 11:12:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/28/2026 08:10:54 PM
- Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim • GlobeNewswire Inc. • 04/24/2026 07:40:00 PM
- Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations • GlobeNewswire Inc. • 04/20/2026 01:15:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 01:28:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/30/2026 09:28:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/28/2026 12:15:44 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 01:19:37 PM
- Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update • GlobeNewswire Inc. • 03/27/2026 01:00:00 PM
- First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement • GlobeNewswire Inc. • 03/27/2026 01:00:00 PM
- Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics • GlobeNewswire Inc. • 03/27/2026 01:00:00 PM
